Hint mode is switched on Switch off
For swift navigation between sections

Roche Holding AG
LEI 549300U41AUUVOAAOB37, SWIFT ROCHCHBHXXX

PDF download

Choose all Reset all
Download Cancel
Organization name
Roche Holding AG
Country name
Switzerland
Country of registration
Switzerland
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
  • M/S&P/F
    *** / *** / ***
Public debt
6,261 mln USD

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and delivers diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company is also involved in the provision of pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research.

Awards

News

29/01/2026 Roche Holding AG's Financial Performance and Outlook
26/11/2025 New issues: Roche Holding AG issued international bonds (USU75000CT18, USU75000CV63) in the amount of USD 500, USD 800 mln maturing in 2030, 2035 respectively.
07/10/2025 DuPont Strengthens Global RO Reach With China Facility Acquisition
07/10/2025 DuPont Strengthens Global RO Reach With China Facility Acquisition
30/11/2023 New issues: Issuer Roche Holding AG released international bonds (XS2726331932, XS2726335099) in the amount of EUR 600, EUR 900 mln maturing in 2027, 2036 respectively.
All organization news

Documentation

IFRS/US GAAP reports

2025
II q eng
IV q eng
2024
II q eng
IV q eng
2023
II q eng
IV q eng
2022
II q eng
IV q eng
2021
II q eng
IV q eng
2020
II q eng
IV q eng
2019
II q eng
IV q eng
2018
II q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Affiliates

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300U41AUUVOAAOB37
  • SWIFT
    ROCHCHBHXXX
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • ICB
    4,500 Health Care
  • CIK
    0000896566
  • UID
    CHE101602521
Registration is required to get access.